๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Venlafaxine and treatment-resistant depression

โœ Scribed by Michael E. Thase; Edward S Friedman; Robert H. Howland

Publisher
John Wiley and Sons
Year
2000
Tongue
English
Weight
78 KB
Volume
12
Category
Article
ISSN
1091-4269

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Venlafaxine. Pharmacology and therapeuti
Venlafaxine. Pharmacology and therapeutic potential in the treatment of depression
โœ Frances E. Burnett; Timothy G. Dinan ๐Ÿ“‚ Article ๐Ÿ“… 1998 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 158 KB ๐Ÿ‘ 2 views

Venlafaxine is the ยฎrst available antidepressant of the structurally novel SNRI (serotonin noradrenaline-reuptake inhibitor) class of drugs. It resembles the tricyclics in its ability to inhibit presynaptic reuptake of both serotonin and noradrenaline to a clinically signiยฎcant degree. However, it d

Clomipramine augmentation in treatment-r
Clomipramine augmentation in treatment-resistant depression
โœ Jay D. Amsterdam; Felipe Garcรญa-Espaรฑa; Martin Rosenzweig ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 80 KB

In depression that is resistant to tricyclic antidepressant (TCA) therapy, the substitution of a selective serotonin re-uptake inhibitor (SSRI), clomipramine, or a monoamine oxidase (MAO) inhibitor has been recommended. However, adding an additional antidepressant medication from a different drug cl

Efficacy of venlafaxine in geriatric dep
Efficacy of venlafaxine in geriatric depression
โœ Jeffrey P. Staab; Dwight L. Evans ๐Ÿ“‚ Article ๐Ÿ“… 2000 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 60 KB ๐Ÿ‘ 1 views
Immune Disturbances in Treatment-Resista
Immune Disturbances in Treatment-Resistant Depression: Modulation by Antidepressive Treatments
โœ MICHAEL MAES; ERIC VANDOOLAEGHE; FRAN VAN HUNSEL; TANIA BRIL; PAUL DEMEDTS; ANNI ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 165 KB

Recently, there were some reports that major depression is accompanied by signiยฎcant alterations in the percentage and number of peripheral blood mononuclear cells (PBMCs), such as increased number of CD4 T cells, B cells (e.g. CD19 , CD21 ), number of leukocytes, monocytes and neutrophils and an in